Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies Authors: Angeliki Andrikopoulou, Flora Zagouri, Kallirroi Goula, Dimitrios Haidopoulos, Nikolaos Thomakos, Anna Svarna, Meletios-Athanasios Dimopoulos, Michalis Liontos Published: 2024 ABSTRACT AbstractHuman epidermal growth factor receptor 2 (HER2) overexpression emerges as an attractive therapeutic target in gynecological malignancies. Recently, Trastuzumab-Deruxtecan (T-DXd) has shown substantial efficacy in HER2 overexpressing carcinomas, most prominently in ovarian, endometrial and cervical patients. We have examined the efficacy of T-DXd in patients with metastatic endometrial, ovarian and cervical malignancies that were treated in the Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens. Methods Patients with gynecological malignancies with HER2 expression 2 + /3 + as assessed by immunohistochemistry (IHC) that were treated with T-DXd were retrospectively identified. Patients received T-DXd intravenously at a dose of 5.4 mg/kg every 3 weeks until disease progression or unacceptable toxicity. Results In total, 10 patients treated with T-DXd for recurrent/metastatic disease were identified. Regarding histology, there were 5 patients with uterine neoplasms (serous carcinoma (n = 3), uterine carcinosarcoma (n = 1), uterine leiomyosarcoma (n = 1)), 1 patient with squamous cervical carcinoma and 4 patients with ovarian cancer (ovarian carcinosarcoma (n = 2), high-grade serous carcinoma (n = 1) and mucinous ovarian carcinoma (n = 1)). Median age was 65.4 years (25th-75th percentile, 58.1–75.2 years). 5 patients had HER2 expression 3 + by IHC and 5 patients had HER2 expression 2 + . Median number of previous lines of therapy was 4 (range 2–6), 2 patients with uterine serous carcinoma were pretreated with trastuzumab and 4 patients had already received immunotherapy. In the entire cohort median progression-free survival (PFS) was 5.4 months (95%CI 0.8–9.8 months). Regarding responses, 5 patients had partial response (including 2 patients that were pretreated with trastuzumab), 1 patient had stable disease at 12 weeks and 4 patients had disease progression at initial assessment. All patients but one that derived clinical benefit had HER2 3 + expression. Discussion In the real-world setting, T-DXd showed activity in a cohort of heavily pre-treated patients with HER2-expressing gynecological malignancies.Keywords: Gynecologic cancer, HER2, T-DXd, DS-8201, Endometrial cancer, Ovarian cancer, Trastuzumab deruxtecan Introduction Gynecological malignancies constitute an important public health issue. Ovarian, uterine and cervical cancer account each year for over 650.000 deaths worldwide indicating that further improvement in prevention, early diagnosis and treatment of these diseases is necessary [1]. Recently, advances in the molecular characterization of these malignancies have conferred significantly in the development of new therapeutic options with proven survival benefit [2–4]. This is reflected in the improved survival recorded in epidemiological studies except for uterine cancer that is characterized by both increased incidence and decreased survival in the US in contrast to most of the other malignancies [5]. Newly developed biomarker-driven targeted therapies were based on the delineation of the molecular biology of gynecological cancers. Thus, endometrial cancer is classified in four molecular subtypes according to the TCGA analysis [6]: a. the ultra-mutated group with recurrent mutations in the exonuclease domain of DNA polymerase epsilon (POLE-mutant), b.the hypermutated group of patients characterized by microsatellite instability or deficiency of the DNA Mismatch Repair mechanism (MSI/MMRd), c. the copy number-low subgroup and d.the p53-aberrant subtype that predominantly includes uterine serous carcinomas. This type of analyses has also revealed recurrent targetable genetic alterations shared among all gynecological malignancies. Such an example is the gene amplification of the human epidermal growth factor receptor 2 (HER2/ERBB2). According to the TCGA data, ERBB2 amplification is detected in 27% of uterine serous carcinomas [7], while HER2 overexpression defined as HER2 immunohistochemistry (IHC) of either 2 + (moderate) or 3 + (strong) is identified in 44% of all endometrial carcinomas and up to 60% of serous tumors [8]. In other gynecological malignancies, HER2 positivity is also observed in 2–6% of cervical carcinomas [9–11] and 2%-66% of ovarian cancers, mainly in mucinous tumors (23%) and non-BRCA1/2 mutant patients [12–16]. Intratumoral heterogeneity, different methods of detection (IHC, FISH) and interobserver variability are the main reasons for the wide range of detected positivity [16]. Whatever the HER2 overexpression rate however it provides undoubtedly a new target for the treatment of gynecologic cancer. Recently, antibody–drug conjugates (ADCs) have gained attention for the treatment of gynecologic malignancies. Mirvetuximab soravtansine-gynx (MIRV) an ADC targeting folate receptor α (FRα) and tisotumab vedotin-tftv a tissue factor-directed ADC were recently approved for the treatment of recurrent ovarian and cervical cancer respectively [17, 18]. Similarly, trastuzumab deruxtecan is a next-generation HER2-targeting ADC that has exhibited efficacy in a variety of solid tumors [19]. Trastuzumab deruxtecan was granted first FDA approval in May 2022 for the second line treatment of HER2-positive metastatic breast cancer and subsequently in August 2022 for HER2-low metastatic disease. However, trastuzumab deruxtecan has also proved tumor agnostic efficacy in HER2-positive tumors and has also received approval for use in gastric cancer and advanced non-small cell lung cancer (NSCLC) with an activating HER2 (ERBB2) mutation. Recently, DESTINY-PanTumor02 Phase II Trial explored the role of trastuzumab deruxtecan in advanced or metastatic HER2-expressing (IHC 3 + or 2 +) solid tumors that have progressed after at least one prior systemic treatment [20]. This basket trial confirmed that trastuzumab deruxtecan results in significant objective responses in HER2-expressing gynecological cancers – cohorts of ovarian, endometrial and cervical cancer patients were included in the study – accompanied by survival gains in comparison to historical controls. In addition, the STATICE trial demonstrated the efficacy of trastuzumab deruxtecan in previously treated HER2-expressing (IHC ≥ 1 +) metastatic uterine carcinosarcomas [21]. Unprecedented objective responses were noted in patients with both high HER2 expression (IHC 2 + and 3 +) (ORR: 54.5%) and low HER2 expression (IHC 1 +) (ORR: 70%) [21] resulting in significant durations of response in both populations (6.9 months in the HER2-high group and 8.1 months in the HER2-low group. Based on the above-described efficacy, FDA granted accelerated approval of trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options in April 2024. Since clinical data of trastuzumab deruxtecan in gynecological malignancies is limited, we undertook a retrospective study to describe efficacy of this ADC in the real-world setting in patients with HER2-expressing gynecological cancer (endometrial, cervical and ovarian cancer) treated in our Institution. Patients and methods Patients and treatment We retrospectively identified all patients with HER2-expressing (HER2 IHC score 2 + and 3 +) gynecological malignancies (ovarian, cervical and endometrial cancer) treated with trastuzumab deruxtecan in the Oncology Unit of Alexandra General Hospital, National and Kapodistrian University of Athens. HER2 IHC was performed according to ASCO/CAP HER2 testing guideline for breast cancer which is based on circumferential membranous staining pattern using the DAKO A0485 polyclonal antibody [22]. The administration of this regimen was approved by the National Drug Organization (EOF) and National Organization for Health Care Services (EOPYY). The study has been performed in accordance with the 1964 Helsinki Declaration and has been approved by the Institutional Review Board of Alexandra University Hospital. A written informed consent was obtained from all patients included in this study. Patients received intravenous trastuzumab deruxtecan at a dose of 5.4 mg/kg every 3 weeks until disease progression or unacceptable toxicity. Statistical analysis All data were extracted from the patients’ medical records and were analyzed in a specifically designed database of the SPSS statistical package (SPSS Inc, Armonk, NY) version 24. Baseline demographic and clinicopathological characteristics were recorded at time of enrollment including: age at initial diagnosis, type of malignancy, histology, stage at diagnosis, grade, HER2 status, microsatellite instability (MSI) status, type of surgery performed, ECOG performance status, prior treatments and their duration. At data cut-off, duration and number of trastuzumab deruxtecan cycles administered, best response to trastuzumab deruxtecan and overall survival were recorded. Disease progression was evaluated based on imaging assessment with computed tomography (CT) scans by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. Patients who had not experienced disease progression at the time of database closure (May, 2024) were censored at the date of last follow-up. Progression-free survival was calculated from the initiation of treatment with trastuzumab deruxtecan until disease progression or last follow-up. Overall survival was calculated from the initiation of treatment until death or last follow-up. Kaplan–Meier estimates were used to describe and visualize OS and PFS. Results Clinicopathological characteristics Overall, ten patients with HER2-expressing (HER2 IHC score 2 + and 3 +) metastatic gynecological malignancies that received trastuzumab deruxtecan in our Oncology Department were identified. Clinicopathological characteristics of the patients in the entire cohort and per histology are presented in Table 1. More specifically, our cohort included 5 patients with uterine cancer, 4 patients with ovarian cancer and one patient with cervical cancer. Median age of the patients was 65.4 years (25th-75th percentile, 58.1–75.2 years). The majority of patients (80%) was presented with advanced disease (stage III/IV) at initial diagnosis and received surgical treatment independent of the type of cancer. All patients were heavily pretreated and the median number of previous lines of therapy was 4 (range 2–6), including two patients with uterine serous carcinoma that had previously received trastuzumab and 4 patients that had already received immunotherapy. Table 1Clinicopathological characteristics of patients with HER2-expressing gynecologic cancer treated with trastuzumab deruxtecanCharacteristicTotal N = 10Uterine cancer N = 5Ovarian cancer N = 4Age at diagnosis, median (range), years65.4 (58.1–75.2)66 (55–78)66 (56–75)HistologyEndometrial cancer5 (50%) Serous3 (60%) Carcinosarcoma1 (20%) Leiomyosarcoma1 (20%)Ovarian cancer4 (40%) Carcinosarcoma Mucinous3 (50%) Serous1 (25%)Cervical cancer1 (10%)1 (25%)Initial Stage I/II2 (20%)1 (20%)1 (25%) III/IV8 (80%)4 (80%)3 (75%)Surgery YES8 (80%)4 (80%)4 (100%) NO2 (20%)1 (20%)0 (0%)ECOG Performance status 0/110 (100%)5 (100%)4 (100%)First line chemotherapy Paclitaxel/Carboplatin8 (80%)4 (80%)4 (100%) Other2 (20%)1 (20%)-Number of previous chemotherapy regimens, median (range)4 (2–6)4 (2 – 10)2.5 (1 – 4)HER2 immunohistochemistry 2 + 5 (50%)3 (60%)3 (75%) 3 + 5 (50%)2 (40%)1 (25%)PFS to trastuzumab deruxtecan, median (range), months5.4 (95%CI 0.8–9.8) Clinicopathological characteristics of patients with HER2-expressing gynecologic cancer treated with trastuzumab deruxtecan Trastuzumab deruxtecan efficacy in the entire cohort Trastuzumab deruxtecan was administered after disease progression in all approved therapies. Objective responses were noted in 5 patients (all partial responses), one patient had stable disease at 12 weeks and 4 patients had disease progression at initial assessment. In the entire cohort, median PFS was 5.4 months (95%CI 0.8–9.8 months) (Fig. 1). All patients were alive at data cut-off. Considering HER2 expression, none of the five patients with HER2 IHC 3 + expression had disease progression as best response to treatment with trastuzumab deruxtecan. More specifically four patients had partial response and one patient had stable disease as best response to treatment. Four out of five patients with HER2 IHC 2 + expression had disease progression at first evaluation and one patient had partial response (Fig. 2). Kaplan Meier curve of PFS to trastuzumab deruxtecan in HER2-expressing gynecological malignancies Swimmer plot of patients receiving trastuzumab deruxtecan for HER2 IHC 3 + / 2 + gynecologic cancer Trastuzumab deruxtecan efficacy per tumor type HER2 IHC expression and objective response to trastuzumab deruxtecan per type of cancer and histology are presented in Table 2. Partial responses were recorded in five patients. More specifically, three patients had serous uterine carcinoma, two with HER2 IHC expression 3 + (Fig. 3a) that had already received treatment with trastuzumab and one patient with 2 + expression. Of interest, both trastuzumab-pretreated cases responded to subsequent trastuzumab deruxtecan treatment. Three patients with carcinosarcoma, one uterine and two ovarian, were included in our cohort. In carcinosarcoma cases, HER2 IHC expression was detected only in the epithelial component (Fig. 3b). One patient with ovarian carcinosarcoma and HER2 3 + expression had stable disease as best response. Among the two epithelial ovarian cancer cases, one patient with high grade serous carcinoma and one patient with mucinous carcinoma were included. Both had HER2 2 + IHC expression (Fig. 3c) and the patient with the mucinous carcinoma was the only ovarian cancer patient that responded to trastuzumab deruxtecan. Finally, the one patient with metastatic squamous cervical cancer with HER2 3 + expression responded to trastuzumab deruxtecan treatment and currently treatment is ongoing. Table 2HER2 IHC expression and objective responses per caseLocationHistologyAgeHER2 IHC expressionLine of therapyPrior anti-HER2therapyPrior immunotherapyObjective ResponseUterineSerous763 + 4HerceptinYesPRUterineSerous553 + 3HerceptinYesPRUterineSerous652 + 5NoYesPDUterineLMS663 + 4NoNoPRUterineCarcinosarcoma632 + 3NoNoPDCervicalSquamous683 + 2NoYesPROvarianCarcinosarcoma592 + 6NoNoPDOvarianCarcinosarcoma723 + 4NoNoSDOvarianMucinous742 + 2NoNoPROvarianSerous552 + 6NoNoPD HER2 IHC expression and objective responses per case a Uterine serous endometrial carcinoma (a) H&E hematoxylin and eosin staining and (b) HER2 3 + IHC expression b Uterine carcinosarcoma with the (a) carcinoma component with (b) HER2 2 + IHC expression and the (c) chondrosarcomatous sarcoma component with (d) no HER2 IHC expression. c Mucinous carcinoma of the ovary with HER2 2 + IHC expression Discussion Trastuzumab deruxtecan has recently emerged as a promising treatment option in pretreated HER2-expressing solid tumors including gynecological cancers based on the DESTINY-PanTumor02 Phase II Trial [20]. We retrospectively identified all patients that received trastuzumab deruxtecan in this setting to evaluate efficacy in the real-world setting. To our knowledge, this is the first study reporting real world data on this novel treatment approach in gynecological cancer except for one Phase II trial [20] and a small cohort of uterine carcinosarcomas [21]. The DESTINY-PanTumor02 trial presented impressive efficacy results for trastuzumab deruxtecan in HER2 expressing gynecological cancers [20]. In our cohort of patients, we have noted similar responses despite including patients that were heavily pretreated and frequently exposed previously to trastuzumab and/or immunotherapy. Median number of previous treatment lines was 4 (range 2–6) in our study whereas the same number was 2 for endometrial/cervical cancer and 3 for ovarian cancer in the DESTINY-PanTumor02 Phase II Trial. This is possibly the main reason for the numerically lower median PFS noted in our study. These data further support the role of trastuzumab deruxtecan in the treatment algorithm of relapsed/metastatic gynecological carcinomas. Objective responses were noted in half of the patients enrolled, analogously with the data of the phase II trial for gynecological carcinomas. Indeed, median PFS was 5.4 months (95%CI 0.8–9.8 months)) in this heavily pretreated population. Response was 60% in patients with endometrial cancer and 50% in ovarian cancer patients. Of note, ORR was 100% in patients with HER2 IHC 3 + gynecological tumors. In DESTINY-PanTumor02 trial, ORR was 57.5% for endometrial cancer (95% CI, 40.9 to 73.0) and median PFS was 11.1 months. However, responses were lower in the subgroups of patients with cervical and ovarian cancer [20]. These data come in agreement with our results. As highlighted in our study, the greatest benefit is observed among patients with HER2 IHC 3 + expression. ORR was 80% in patients with HER2 IHC 3 + disease in our study. Similarly, ORR was as high as 85% in HER2 IHC 3 + endometrial cancer and 64% in HER2 IHC 3 + ovarian cancer in DESTINY-PanTumor02 Phase II Trial. Both studies provide evidence that patients with HER2 IHC 3 + gynecological malignancies derive the greatest benefit of Trastuzumab Deruxtecan and are thus the ideal candidates to receive the treatment early. It should be noted that people with HER2-positive endometrial cancer where not analyzed separately on Phase III trials of immunotherapy as first line treatment [2, 23]. Consequently, there are no data regarding the benefit of immunotherapy in HER2-positive endometrial cancer and more importantly whether HER2-targeted treatment should be administered earlier in the first line setting. Trastuzumab deruxtecan has shown great antitumor effect in HER2 3 + IHC uterine and ovarian carcinosarcoma cell lines and patient-derived xenografts [24, 25]. These results were confirmed in patients with uterine HER2-expressing (HER2 IHC ≥ 1 +) carcinosarcoma by the STATICE Phase II trial [21]. In our study, there was no response achieved with trastuzumab deruxtecan in patients with carcinosarcoma and only one patient had stable disease. Overall, HER2 expression was low and no major responses were observed in carcinosarcoma cases. In the STATICE trial trastuzumab deruxtecan demonstrated antitumor activity in both HER2-high and HER2-low uterine carcinosarcoma with a median PFS of 6.2 and 6.7 months respectively. Uterine carcinosarcoma is now believed to derive from the dedifferentiation of the carcinoma to the sarcoma component. There is evidence that HER2 expression is higher in the carcinomatous component where it can be identified in up to 19% of the cases in serous and mixed carcinoma [26]. In the sarcomatous component however there is HER2 2 + IHC expression in 11% of the tumors and HER2 3 + in none of them [26]. Indeed, intratumoral HER2 heterogeneity is observed in 25% of all cases and in 38% of HER2-positive tumors [26]. Despite this high HER2 heterogeneity in uterine carcinosarcomas, the efficacy of trastuzumab deruxtecan in these tumors may be explained partially through the bystander killing effect of the drug which enables the delivery of the cytotoxic payload not only to HER2 positive cells but also to the adjacent HER2 negative ones. Although the STATICE trial and our results provide evidence that trastuzumab deruxtecan is an alternative therapeutic option for uterine carcinosarcomas, the aggressive nature of the disease and the high recurrence rate create the need of more solid data before the establishment of this regimen as a treatment mainstay for carcinosarcoma. The main strength of our study is the current lack of data on the efficacy of trastuzumab deruxtecan in HER2-expressing gynecological malignancies. To date, only one Phase II trial [20], one study in uterine carcinosarcoma [21] and some case reports [27, 28] have evaluated the role of trastuzumab deruxtecan in HER2-expressing gynecological tumors. However, we need more studies to evaluate the efficacy of trastuzumab deruxtecan in gynecologic malignancies, especially Phase III trials. The major limitation is the limited sample size. In addition, there are no guidelines on the way of HER2 evaluation in endometrial cancer. In our study, scoring was performed according to guidelines set forth by the 2023 ASCO/College of American Pathologists (ASCO-CAP) for breast cancer [22]. According to these guidelines, HER2 IHC3 + are considered tumors with circumferential membrane staining that is complete, intense and in > 10% of tumor cells while HER2 IHC 2 + are those tumors with weak to moderate complete membrane staining observed in > 10% of tumor cells [22]. The impetus for revisiting the ASCO-CAP guideline was the 2022 publication of the DESTINYBreast04 trial. Most studies have also evaluated HER2-expression according to the breast cancer protocol in endometrial cancer specimens [29, 30]. However, the DESTINY-PanTumor02 Phase II Trial and STATICE Phase II trial evaluated HER2 expression using current ASCO/College of American Pathology guidelines for gastric cancer [20, 21, 31]. According to the gastric scoring system, HER2 IHC3 + tumors are those exhibiting strong, complete, basolateral or lateral membranous reactivity in ≥ 10% of tumor cells and HER2 IHC 2 + those with weak to moderate, complete, basolateral or lateral membranous reactivity in ≥ 10% of tumor cells. Indeed, there are some key differences between HER2 immunohistochemistry testing in breast and gastric cancer. First, the membranous distribution of the antibody in tumor cells of breast cancer is predominantly circumferential, whereas in gastric cancer, it is incomplete, basolateral (“U”-shaped) or lateral (parallel lines) [32]. In addition, intratumoral heterogeneity is more common in gastric tumors. We thus need a unified and predefined way to evaluate HER2 expression in gynecologic malignancies. Since the DESTINY-PanTumor02 Phase II study is based in the HER2 scoring system for gastric cancer transferring the breast cancer scoring system to this population could affect patient selection. HER2 expression in gynecological tumors should be evaluated according to a single scoring system that is familiar to pathologists. Another limitation is the heterogeneity of our population. Conclusions Trastuzumab deruxtecan showed clinical activity in a cohort of heavily pre-treated patients with HER2-expressing gynecological malignancies in the real-world setting. Further Phase III trials should be conducted to investigate the role of trastuzumab deruxtecan in this population. Acknowledgements Not applicable. Abbreviations Human epidermal growth factor receptor 2 Trastuzumab deruxtecan Immunohistochemistry Progression-free survival The Cancer Genome Atlas Response Evaluation Criteria in Solid Tumors ASCO/College of American Pathologists DNA polymerase epsilon Mismatch repair mechanism Antibody–drug conjugate Folate receptor α Microsatellite instability Food and Drug Administration Non-small cell lung cancer Eastern Cooperative Oncology Group Overall response rate Authors’ contributions Conceptualization: Michalis Liontos, Zagouri Flora, Meletios-Athanasios Dimopoulos, Nikolaos Thomakos; Data curation: Michalis Liontos, Angeliki Andrikopoulou, Anna Svarna, Nikolaos Thomakos, Kallirroi Goula; Investigation: Angeliki Andrikopoulou, Anna Svarna, Kallirroi Goula. Formal analysis: Angeliki Andrikopoulou, Kallirroi Goula, Michalis Liontos; Methodology: Michalis Liontos, Angeliki Andrikopoulou, Anna Svarna; Project administration: Michalis Liontos, Zagouri Flora, Meletios-Athanasios Dimopoulos, Dimitrios Haidopoulos; Supervision: Michalis Liontos, Flora Zagouri, Meletios-Athanasios Dimopoulos, Dimitrios Haidopoulos; Writing—original draft: Angeliki Andrikopoulou, Nikolaos Thomakos, Michalis Liontos, Flora Zagouri; Writing—review & editing: Michalis Liontos, Flora Zagouri, Meletios-Athanasios Dimopoulos, Dimitrios Haidopoulos. Funding This research received no external funding. Data availability Data presented in our study can be found in the patient’s archive that is safely stored in our Institution. The patient’s archive is available from the corresponding author upon request. Declarations Ethics approval and consent to participate "The study has been performed in accordance with the 1964 Helsinki Declaration and has been approved by the Institutional Review Board of Alexandra University Hospital. A written informed consent was obtained from all patients included in this study.” Consent for publication Not applicable. Competing interests ML has received honoraria from Roche, Astra Zeneca, Astellas, MSD, Janssen, Bristol-Myers-Squibb and IPSEN. MAD has received honoraria from participation in advisory boards from Amgen, Bristol-Myers-Squibb, Celgene, Janssen, Takeda. FZ has received honoraria for lectures and has served in an advisory role for Astra-Zeneca, Daiichi, Eli-Lilly, Merck, Novartis, Pfizer, and Roche. The remaining authors declare no conflict of interest. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data presented in our study can be found in the patient’s archive that is safely stored in our Institution. The patient’s archive is available from the corresponding author upon request.